Official websites use .gov
Secure .gov websites use HTTPS
Medications for obesity management: effectiveness and value : final evidence report
Medications for obesity management: effectiveness and value : final evidence report
- Collection:
- Health Policy and Services Research
- Author(s):
- Atlas, Steven J., author
Beinfeld, Molly, author
Lancaster, Victoria, author
Nhan, Emily, author
Moradi, Ashton, author
Rind, David M., author
Pearson, Steven D., author
Beaudoin, Francesca L., author
Kim, Kibum, author
Lien, Pei-Wen, author
Shah, Kanya, author
Touchette, Daniel R., author - Contributor(s):
- Institute for Clinical and Economic Review, issuing body.
New England Comparative Effectiveness Public Advisory Council, issuing body. - Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, October 20, 2022
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Bupropion
Glucagon-Like Peptide-1 Receptor Agonists
Liraglutide
Obesity -- drug therapy
Obesity Management -- methods
Phentermine
United States - Genre(s):
- Technical Report
- Abstract:
- Obesity is a common chronic disease that increases the risk of other conditions such as diabetes mellitus, cancer, and heart disease as well as death. Individuals with overweight and obesity also face considerable social stigma that can have both direct (e.g., mental health, wellbeing) and indirect consequences (e.g., engagement with health care providers). Body mass index (BMI, weight in kilograms/height in meters) is commonly used to assess for obesity because it is easy to measure and correlates with body fat measurements. In 2015, the number of adults in the United States (US) with overweight or obesity was estimated to be 79 million and 70 million, respectively. The prevalence of obesity surpassed 40% of US adults in 2018, but among some racial and ethnic groups obesity is even more prevalent with higher proportions for Hispanic adults and highest proportions among non-Hispanic Black women. The direct medical costs attributable to obesity are staggering, estimated to be $260 billion in the US in 2016. Given the high of obesity and its many adverse clinical and cost consequences, cost-effective treatments for this chronic condition are imperative. Interest in medications to reduce weight and improve health in individuals with obesity has increased due to more non-surgical alternatives and data suggesting that newer medications have an acceptable safety profile and may be more effective in promoting weight loss. Limitations of medications for weight loss include side effects that lead to patient discontinuation, and weight regain when stopped. Under a chronic disease framework, clinical experts concluded that longterm anti-obesity medication use would likely be needed, particularly to prevent complications of obesity such as heart disease. This Report reviews four medications approved by the US Food and Drug Administration (FDA): semaglutide (Wegovy®, Novo Nordisk, June 2021), liraglutide (Saxenda®, Novo Nordisk, 2014), phentermine/topiramate (Qysmia®, Vivus, 2012), and bupropion/naltrexone (Contrave®, Currax Pharmaceuticals, 2014). Semaglutide and liraglutide are glucagon-like peptide-1 (GLP-1) receptor agonists that are also approved for diabetes mellitus and given by subcutaneous injection, whereas phentermine/topiramate and bupropion/naltrexone are combination oral agents that work via other mechanisms. Other promising therapies (e.g., tirzepatide) are still under investigation and are therefore not included in the scope of this review.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918506283206676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918506283206676